Barnett Fellowship in Pharmacology

The award is available to UB PhD students doing their dissertation research in Pharmacology and Toxicology laboratories.

Top priority is given to students enrolled in the PhD program in Pharmacology.

• Materials/supplies/equipment to support research (computer, software, books, etc).
• Travel to conferences to present research papers or posters (transportation, hotel, food per University guidelines).
• Other research-related expenses approved by the chair.

1. A narrative description of your thesis research project using jargon-free language appropriate for a non-specialized audience as often as possible. A timeline would be very helpful (noting when you will attend meetings, when you expect to complete specific experiments, etc). Please include a title at the top of your narrative, and adhere to the following formatting specifications: 2 pages or less, single-spaced. 12-point font; one-inch margins.
2. A brief statement outlining the proposed use of the funds, not exceeding $2,000.
3. E-mail one single PDF document of the narrative and budget proposal to Graduate Program Coordinator, Liz Marshall.
4. Letter of support from your PI, acknowledging the need for such funding and outlining your accomplishments to-date as a PhD candidate. This letter is to be emailed directly to Liz Marshall.

Applications are due October 31 each year. 

We'll notify you within 1-2 weeks of your application if you are selected as a recipient of the Barnett fellowship.

Allen Barnett, PhD, is a drug development executive who earned his doctorate in pharmacology from the University at Buffalo in 1965. Barnett is president emeritus of Kinex, a pharmaceutical company focused on next-generation therapies for cancer and immunomodulatory diseases. During his tenure at Schering-Plough, he brought several drugs to the marketplace. He also led the effort that resulted in the discovery of Claritin, a non-sedating antihistamine that became the fifth-leading drug in the world, based on sales.